Influenza Session

Emmanuel (Chip) Walter, MD, MPH
Chair, Influenza Work Group

Advisory Committee on Immunization Practices
February 27, 2019
Influenza Work Group

**ACIP Members**
Emmanuel (Chip) Walter (Chair)
Robert Atmar
Kevin Ault
Hank Bernstein
Peter Szilagyi

**Ex Officio Members**
Michael Cooper (NIH)
Cynthia Nolletti (FDA)
Roshan Ramanathan (FDA)
Chris Roberts (NIH)
Susan Wollersheim (FDA)

**Consultants**
Ed Belongia
Jeff Duchin
Wendy Keitel
Jamie Loehr
Kathy Neuzil

**Liaison Representatives**
Sarah Coles (AAFP)
Buddy Creech (PIDS)
Sarah Despres (Consumer Representative)
Sandra Fryhofer (ACP; AMA)
Ian Gemmill (NACI)
Denise Jamieson (ACOG)
Marie-Michèle Léger (AAPA)
Susan Lett (CSTE)
Flor Munoz (AAP)
William Schaffner (NFID)
Rob Schechter (AIM)
Ken Schmader (AGS)
Patsy Stinchfield (NAPNAP)
Tamara Sheffield (AHIP)
Matthew Zahn (NACCHO)
Recap of Influenza Session, October 2018

- Presentation of the PREVENT study of effectiveness of influenza vaccine in preventing hospitalization among pregnant women

- Presentation of study of Fluzone Quadrivalent (Sanofi Pasteur) at a 0.5mL dose for children aged 6 through 35 months
  - Approved by FDA in January 2019
Work Group Discussions Since October 2018

- 2018-19 season U.S. influenza activity

- Interim 2018-19 season vaccine effectiveness estimates (U.S. Flu VE Network)

- Results of the 3rd Vaccine Safety Datalink study of inactivated influenza vaccines (IIVs) and spontaneous abortion (SAB) among pregnant women
  - Follow-up to an earlier study presented to ACIP in October 2017, which detected an association between receipt of IIV and SAB in first 28 days post vaccination when an H1N1pdm09-containing vaccine had also been received the previous season.
Agenda Overview

- **2018-19 U.S. Surveillance Update**
  - Ms. Lynnette Brammer, CDC/NCIRD

- **Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness--US Flu VE Network**
  - Dr. Brendan Flannery, CDC/NCIRD

- **Phase III Randomized Observer-Blind Comparator-Controlled study of Afluria Quadrivalent for Children 6 through 59 months**
  - Dr. Gregg Sylvester, Seqirus

- **Case-Control Study of Inactivated Influenza Vaccine and Spontaneous Abortion in the Vaccine Safety Datalink, 2012-13, 2013-14, and 2014-15**
  - Dr. Jim Donahue, Marshfield Clinic Research Institute

- **Summary and Work Group Considerations**
  - Dr. Lisa Grohskopf, CDC/NCIRD